Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC)

被引：19
|
作者：
Gerratana, Lorenzo [1 ,2 ]
Zhang, Qiang [1 ]
Shah, Ami Naimish [1 ]
Davis, Andrew Adam [1 ]
Zhang, Youbin [1 ]
Wehbe, Firas [3 ]
Qiang, Wenan [1 ]
Flaum, Lisa [1 ]
Finkelman, Brian Steven [4 ]
Gradishar, William John [1 ]
Platanias, Leonidas C. [1 ]
Behdad, Amir [4 ]
Cristofanilli, Massimo [1 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Dept Med,Div Hematol & Oncol, Chicago, IL 60611 USA
[2] Univ Udine, Dept Med DAME, Ple Kolbe 4, I-33100 Udine, UD, Italy
[3] Northwestern Univ, Div Hlth & Biomed Informat, Dept Prevent Med, Chicago, IL 60611 USA
[4] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Dept Pathol, Chicago, IL 60611 USA
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2020年 / 145卷
关键词：
Next generation sequencing; Precision medicine; Clinical utility; Circulating tumor DNA; CELL-FREE DNA;
D O I：
10.1016/j.critrevonc.2019.102856
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Circulating tumor DNA (ctDNA) is gaining momentum as sensitive diagnostic tool for advanced disease characterization because of its ability both to capture the tumor's heterogeneity and its dynamic adaptations. However, the consistency between all the available platforms is still debated. The aim of the study was to explore the performance of the novel diagnostic NGS platform PredicinePLUS (TM) and to compare its results with the clinically available Guardant360 (TM) platform for possible analytical inconsistencies. The study suggests that PredicinePLUS (TM) NGS platform can detect genomic alterations and measure allele frequency in samples of MBC patients and confirmed that different NGS platforms could be potentially compared provided that certain sample management and analytical requirements are met.
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Concordance of circulating tumor DNA (ctDNA) and next-generation sequencing (NGS) as molecular monitoring tools in metastatic breast cancer (MBC)
    Austin, Laura K.
    Avery, Tiffany
    Jaslow, Rebecca
    Fortina, Paolo
    Sebisanovic, Dragan
    Siew, LaiMun
    Zapanta, Aubrey
    Talasaz, AmirAli
    Cristofanilli, Massimo
    [J]. CANCER RESEARCH, 2015, 75
  • [2] The LiquidBiopsy in metastatic breast cancer (MBC): A novel diagnostic platform for next generation sequencing (NGS) of circulating tumor cells (CTCs)
    Strauss, William
    Winer-Jones, Jessamine
    Austin, Laura
    Dempsey, Paul W.
    Cristofanilli, Massimo
    [J]. CANCER RESEARCH, 2015, 75
  • [3] Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with metastatic breast cancer (mBC).
    Pusztai, Lajos
    Chung, Jon
    Young, Lauren
    Schrock, Alexa Betzig
    Hartmaier, Ryan
    Frampton, Garrett Michael
    Gay, Laurie M.
    Stephens, Phil
    Miller, Vincent A.
    Ali, Siraj Mahamed
    Ross, Jeffrey S.
    Vahdat, Linda T.
    O'Shaughnessy, Joyce
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] Investigating oncogenic signaling pathways in inflammatory metastatic breast cancer (MBC) though circulating tumor DNA (ctDNA) next-generation sequencing (NGS)
    Gerratana, Lorenzo
    Davis, Andrew A.
    Mina, Marco
    Jacob, Saya L.
    Zhang, Qiang
    Shah, Ami N.
    D'Amico, Paolo
    Katam, Neelima
    Wehbe, Firas
    Vagia, Elena
    Flaum, Lisa
    Platanias, Leonidas
    Behdad, Amir
    Puglisi, Fabio
    Gradishar, William J.
    Ciriello, Giovanni
    Cristofanilli, Massimo
    [J]. CANCER RESEARCH, 2021, 81 (04)
  • [5] Biomarker analysis by next generation circulating tumor DNA (ctDNA) sequencing in patients with advanced breast cancer
    Li, Huiping
    Wang, Jing
    Rugo, Hope S.
    Zhang, Yan
    Yang, Ling
    Liu, Xiaoran
    Shao, Bin
    Xu, Yaping
    Yang, Liang
    Zhang, Ruyan
    Ran, Ran
    Chang, Lianpeng
    [J]. CANCER RESEARCH, 2018, 78 (04)
  • [6] Next generation sequencing of solid tumor and circulating tumor DNA (ctDNA) in metastatic melanoma
    Carpenter, Erica L.
    Yee, Stephanie S.
    Soucier, Devon
    Morrissette, Jennifer J.
    Xu, Wei
    Harmon, Shannon R.
    Salathia, Neeraj
    Zhao, Yue
    Waters, Jill
    Fan, Jian-Bing
    Schuchter, Lynn Mara
    Amaravadi, Ravi K.
    Karakousis, Giorgos Constantine
    Gangadhar, Tara C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Circulating tumor DNA (ctDNA) as a molecular monitoring tool in metastatic breast cancer (MBC)
    Austin, Laura Katherine
    Fortina, Paolo
    Sebisanovic, Dragan
    Siew, LaiMun
    Zapanta, Aubrey
    Talasaz, AmirAli
    Cristofanilli, Massimo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) longitudinal monitoring of metastatic breast cancer (MBC).
    Costa, Ricardo Lima Barros
    Rossi, Giovanna
    Mu, Zhaomei
    Austin, Laura Katherine
    Rademaker, Alfred
    Gradishar, William John
    Santa-Maria, Cesar Augusto
    Jain, Sarika
    Flaum, Lisa E.
    Giles, Francis J.
    Yang, Hushan
    Cristofanilli, Massimo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Genomic progression, detected by circulating tumor DNA (ctDNA) sequencing, as an early predictor of disease progression in metastatic breast cancer (MBC)
    Velimirovic, M.
    Juric, D.
    Niemierko, A.
    Spring, L. M.
    Vidula, N.
    Malvarosa, G.
    Yuen, M.
    Moy, B.
    Isakoff, S. J.
    Ellisen, L. W.
    Bardia, A.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [10] Targeted Next-Generation Sequencing of Circulating Tumor DNA Mutations among Metastatic Breast Cancer Patients
    Sun, Min-Ying
    Lin, Fang-Qin
    Chen, Lu-Jia
    Li, Hong
    Lin, Wei-Quan
    Du, Hong-Yan
    Yang, Xue-Xi
    Li, Ming
    [J]. CURRENT ONCOLOGY, 2021, 28 (04) : 2326 - 2336
12345